Copyright © 1990 by the European Society of Cardiology.
© 1990 The European Society of Cardiology
Preventive treatment of asymptomatic left ventricular dysfunction following myocardial infarction
Department of Medicine, University of Auckland School of Medicine Auckland, New Zealand
Correspondence: Dr D. N. Sharpe, Department of Medicine, Auckland Hospital, Auckland 1, New Zealand
Progressive asymptomatic ventricular dilatation can occur following myocardial infarction and severe ventricular dysfunction is often present by the time clinical congestive heart failure occurs. In a randomized, double-blind trial, the effects of captopril 25 mg tid, frusemide 40 mg daily and placebo were studied in 90 patients with asymptomatic left ventricular dysfunction (ejection fraction < 45%) 1 week following Q wave myocardial infarction. Left ventricular volumes and function were assessed at intervals during the subsequent year using two-dimensional echocardiography. The frusemide and placebo groups showed significant increases in ventricular volumes with stroke volume index unchanged and ejection fraction slightly reduced, whereas the captopril group showed a significant reduction in left ventricular end-systolic volume index with stroke volume index and ejection fraction increased. At 12 months the difference in the change in ejection fraction from baseline between the captopril and frusemide groups was 10·5% and captopril and placebo groups 9·6% (both P < 0·0001). There was a significant difference in occurrence of clinical heart failure in the placebo group compared with the other groups (P < 0·05). Blood pressure increased significantly within the normal range in the placebo and frusemide groups whereas there was essentially no change from baseline in the captopril group. There was no significant correlation between baseline left ventricular volumes and function and subsequent change, and anterior and inferior infarct subgroups showed similar responses within the treatment groups. In conclusion, captopril improves asymptomatic ventricular dysfunction and prevents clinical heart failure during the year following myocardial infarction. Frusemide may also prevent clinical heart failure but not progressive ventricular dilatation.
Key Words: Captopril • frusemide • left ventricular dysfunction • myocardial infarction
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. J de Kam, A. A Voors, F. Fici, D. J van Veldhuisen, and W. H van Gilst Review: The revised role of ACE-inhibition after myocardial infarction in the thrombolytic/primary PCI era Journal of Renin-Angiotensin-Aldosterone System, December 1, 2004; 5(4): 161 - 168. [Abstract] [PDF]
|
|
|
|
 |
|
 T. J. Wang, D. Levy, E. J. Benjamin, and R. S. Vasan The Epidemiology of "Asymptomatic" Left Ventricular Systolic Dysfunction: Implications for Screening Ann Intern Med, June 3, 2003; 138(11): 907 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hurlen, T. Hole, I. Seljeflot, and H. Arnesen Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction Eur J Heart Fail, March 1, 2001; 3(2): 203 - 207. [Abstract] [Full Text] [PDF]
|
|